Clinical Trials Logo
  1. Home
  2. GVHD, Acute
  3. NCT05718791

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

GVHD,Acute Clinical Trial

Official title:
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease

Clinical Trial Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05718791
Study type Observational
Source Henry Ford Health System
Contact shatha farhan, MD
Phone 3137133910
Email sfarhan1@hfhs.org
Status Recruiting
Phase
Start date May 10, 2023
Completion date March 30, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05855707 - Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis Phase 1
Active, not recruiting NCT04522843 - Analysis of Intestinal Defensin Expression in Acute GVHD
Recruiting NCT05368181 - MAP-guided Preemptive Therapy of aGvHD Phase 2
Recruiting NCT05401955 - Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD) N/A
Withdrawn NCT05443464 - Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD) Phase 1
Not yet recruiting NCT06315309 - Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant Phase 2
Terminated NCT04220632 - A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease Phase 1/Phase 2
Recruiting NCT04284904 - Role of aGVHD Biomarkers on aGVHD Risks
Not yet recruiting NCT06164288 - Safety and Efficacy Study of hAESCs Therapy for aGVHD Phase 1